Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $36.00

Definium Therapeutics (NASDAQ:DFTX) had its target price increased by investment analysts at Royal Bank Of Canada from $20.00 to $36.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 108.21% from the stock’s current price.

A number of other research analysts have also recently weighed in on the stock. Jones Trading started coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Canaccord Genuity Group boosted their price target on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Lifesci Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.11.

Definium Therapeutics Trading Up 1.9%

Shares of NASDAQ DFTX traded up $0.32 during trading on Friday, reaching $17.29. The stock had a trading volume of 223,405 shares, compared to its average volume of 2,295,601. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The company has a market cap of $1.70 billion, a P/E ratio of -8.48 and a beta of 2.57. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.12. The business’s 50-day moving average price is $13.04 and its 200-day moving average price is $11.35.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, equities research analysts predict that Definium Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other news, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BIT Capital GmbH purchased a new position in shares of Definium Therapeutics during the third quarter worth about $26,000. Fifth Third Bancorp lifted its position in Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares during the period. Sound Income Strategies LLC purchased a new position in shares of Definium Therapeutics in the 3rd quarter valued at approximately $46,000. Russell Investments Group Ltd. grew its stake in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Definium Therapeutics by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.